Research programme: pifithrin compounds - Quark Pharmaceuticals

Drug Profile

Research programme: pifithrin compounds - Quark Pharmaceuticals

Alternative Names: Oncology research programme - Quark; PFT; PFT-X; PFT-β; QG-AGC1; QG-AGC6

Latest Information Update: 31 Aug 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Quark Biotech
  • Developer Quark Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Tumour suppressor protein p53 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alopecia

Most Recent Events

  • 10 Mar 2005 Quark is actively seeking strategic partners for development of its oncology portfolio
  • 31 Jul 2003 Preclinical development for Alopecia (Chemotherapy-induced, Prevention)/Chemoprotection in USA (unspecified route)
  • 31 Jul 2003 Preclinical development for Radiation injuries (Prevention)/Radioprotection in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top